Plain-English translation of NCT06385925 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called to treat advanced cancers that carry a specific genetic mutation known as KRAS G12D. The study will first find the right dose and safety profile, then test how well the medication works either alone or combined with other cancer treatments. Researchers are recruiting about 440 people with pancreatic cancer, colorectal cancer, lung cancer, or other advanced solid tumors for this study.
Many people with advanced cancers have this specific KRAS G12D genetic mutation, which is difficult to treat with current therapies. This medication is designed to directly target and disable this mutation, offering a new treatment option for patients who have limited alternatives or whose cancers have stopped responding to standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication by mouth (or receive it as directed) and attend regular clinic visits for safety checks, blood tests, and imaging scans to see how the cancer is responding. The study has multiple phases: first, researchers will find the safest and most effective dose, then test how well it works in larger groups of patients with specific cancer types. Some participants may receive the medication alone, while others may receive it combined with other cancer drugs, depending on which study group they join.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
China